Aquestive Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have reported a 5.2% beneficial ownership stake in Aquestive Therapeutics, Inc. as of September 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 5.3% Stake in Aquestive Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% passive ownership stake in Aquestive Therapeutics Inc. common stock.
NASDAQ
SCHEDULE 13G/A: Venrock Healthcare Capital Partners Amends Aquestive Therapeutics Stake, Reports 2.9% Beneficial Ownership
Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Aquestive Therapeutics, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Douglas K. Bratton and Affiliated Entities Report 11.1% Beneficial Ownership in Aquestive Therapeutics
Douglas K. Bratton and a group of affiliated investment entities have filed an updated Schedule 13G, disclosing a combined beneficial ownership of 11.1% in Aquestive Therapeutics, Inc.'s common stock as of December 31, 2024.